ALKS (alkermes.com) Rasio Nilai Pasar marang Nilai Buku

This price chart for Alkermes plc (ALKS) illustrates valuation trends, reflecting the impact of patent disputes and payment volatility, with the key metric currently at 4.15. Alkermes plc (ALKS) develops mental health treatments, leveraging unique long-acting injection methods and strict FDA oversight. Management has effectively optimized the asset structure, focusing on intellectual property protection and specialized innovations.

For the biopharmaceutical Alkermes plc (ALKS), which invests in "green chemistry" to reduce production toxicity, this ratio reflects the market premium over the value of tangible and intangible assets. By analyzing the company's market-to-book ratio, an investor determines the extent to which quotes are inflated relative to equity, allowing for an assessment of the risk of overpayment at the current liquidity level.